General Information
Revision date
2018-08-08
Product name
Hydroxyurea Capsules, For Oral Use
Product Synonyms
DROXIA® (hydroxyurea) Capsules, 200, 300, and 400 mg; HYDREA®
1.2.1 Relevant identified uses
This material is a finished drug product for patient use. It is used in the treatment of cancer. It is used to treat certain blood disorders
Emergency telephone
Australia (Sydney) +(61)-290372994
Icons in SDS
Company Information
company name
Bristol-Myers Squibb Australia Pty Ltd
GHS Information
Signal word
Danger
Section 2
SECTION 2: Hazards identification
UN Globally Harmonized System (GHS)
2.1 Classification of the substance or mixture
Germ Cell Mutagenicity - Category 2 Toxic To Reproduction - Male Reproductive Toxicity - Category 1B Toxic To Reproduction - Developmental Toxicity - Category 1B Effects On Or Via Lactation Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1
Signal word
Danger
Hazard statements
Suspected of causing genetic defects. May damage fertility May damage the unborn child (developmental toxicity) . May cause harm to breast-fed children. Causes damage to organs (bone marrow, male reproductive organs, gastrointestinal tract, liver, skin, pancreas, kidney, lungs, peripheral nervous system) through prolonged or repeated exposure.
Precautionary statements
Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Use personal protective equipment as required. Do not breathe dust. Wash thoroughly after handling. Do not eat, drink or smoke when using this product.
